ClinicalTrials.Veeva

Menu

Efficacy and Safety of Allogenic Stem Cell Product(CARTISTEM®) for Osteochondral Lesion of Talus

H

Hyundai Bioland

Status and phase

Completed
Phase 3

Conditions

Chondral or Osteochondral Lesion of Talus

Treatments

Biological: CARTISTEM®
Procedure: Microfracture

Study type

Interventional

Funder types

Industry

Identifiers

NCT04310215
CARTISTEM_2019_01

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of adding CARTISTEM®(allogenic umbilical cord blood-derived stem cell product) on microfracture, a currently standard treatment for OLT, in patients with talar chondral or osteochondral defect.

Enrollment

102 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Talar chondral/osteochondral lesion confirmed by radiographical exam at screening or diagnosis, an AOFAS score of 75 or below

  2. Ankle joint pain/stiffness with no response to conservative treatment for more than 12 weeks

  3. Ankle joint cartilage injury of defect of ICRS grade Ⅳ in MRI

  4. Male or female aged more than 18

  5. A one-sided lesion

  6. Appropriate function of blood clot: PT(INR) < 1.5×ULN, aPTT <1.5×ULN

  7. Appropriate renal function: Creatinine ≤ 2.0 ㎎/㎗, Proteinuria ≤ trace

  8. Appropriate hepatic function: Total bilirubin ≤ 2.0 ㎎/㎗, AST/ALT ≤ 100 IU/L

  9. No evidence of auto-immune disorder: According to investigator's judgement based on relevent symtom and physical exam, anti-nuclear antibody and anti-thyroglobulin antibody tests are able to performed and confirmed negative (If positive, there are possible cases according to diagnostic opinion of medical department)

  10. No surgery or radiotherapy for the same ankle joint within 6 weeks

  11. Female patients agreeing with maintenance of contraception* during study period

    *hormone contraceptive, implants of intrauterine device or intrauterine system, double barrier contraception[Concurrent use of diaphragm or cervical occlusive cap and male condom], surgical sterilisation, etc.

  12. No chronic ligament instability more than grade Ⅲ (Grade 0: none, Grade Ⅰ: 1~5㎜, GradeⅡ: 5~10㎜, Grade Ⅲ: >10㎜)

  13. Patients agreeing with participation in this study and signed on informed consent by their own will

Exclusion criteria

  1. Degenerative arthritis in ankle(Kellgren Lawrence Grade 3-4)

  2. Autoimmune disease

  3. Infectious disease need to administration of parenteral antibiotics

  4. Myocardial infarction, congestive heart failure, other serious cardiac disorder or uncontrolled resistant hypertension

  5. Serious medical disease(Ex. Kidney disease such as chronic renal failure or Glomerulonephritis, etc., acute/chronic liver disease such as liver cirrhosis, fatty liver etc., medical history of malignancy*)

    *Complete remission status is possible.

  6. Pregnancy or breast-feeding

  7. Psychiatric history or epilepsy

  8. Alcohol abuse

  9. Heavy smoker

  10. Chronic inflammatory disease such as rheumatoid arthritis

  11. Participants other clinical trials within 4 weeks

  12. Administration of immunosuppressing agents such as Cyclosporin A or azathioprine within 6 weeks

  13. Patients with acute ligament injury and clinically significant chronic ligament instability

  14. Patients treated with surgery or cell therapy product for the same disease

  15. Patients with hypersensitivity or allergy history to bovine protein, hyaluronic acid and gentamicin

  16. Other inappropriate patients determined by the principal investigator

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

102 participants in 2 patient groups

Microfracture + CARTISTEM®
Experimental group
Description:
CARTISTEM® is added on the lesion as a single dose of 500 ㎕/㎠ according to the defect size after arthroscopic curettage and microfracture.
Treatment:
Biological: CARTISTEM®
Microfracture
Active Comparator group
Description:
Standard treatment of arthroscopic curettage and microfracture is performed for cartilage defect.
Treatment:
Procedure: Microfracture

Trial contacts and locations

6

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems